DOSSIER · 13F-HR · Q4 2025

Novo Holdings A/S

$1.3B in tracked AUM across 24 positions as of Q4 2025.

NH
CIK 0001388325 · last filed Dec 31, 2025
Total AUM
$1.3B
as of Q4 2025
Holdings
24
positions
Whale Score
68
68
tracked
Activity
no data
changes this Q
AI Analysis · Q4 2025

Portfolio Overview

Novo Holdings A/S reported a significant portfolio contraction for the period ending September 30, 2025, with total assets under management (AUM) decreasing by 28.1%, dropping from $1.42 billion to $1.02 billion. This reduction was driven by a combination of active portfolio management—specifically a large divestment from broad market exposure—and a reduction in position sizes across several key names. The portfolio is highly concentrated, containing only 20 holdings. Thi...

Key Holdings

The portfolio is dominated by a mix of alternative assets and high-growth biotechnology names. The largest position is Brookfield Corp (BN) at $159.85 million, representing 15.69% of the portfolio. This significant allocation to a diversified alternative asset manager suggests a desire for stable, long-term value exposure outside of the volatile public equity markets.

Quarter at a glance — Q4 2025

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q4 2025.

#HoldingValueSharesWeight
01
BN
BROOKFIELD CORP
$160M3.5M12.5%
02
EWTX
EDGEWISE THERAPEUTICS INC
$133M5.3M10.3%
03
N07059210
ASML HOLDING N V
$122M114K9.5%
04
MIRM
MIRUM PHARMACEUTICALS INC
$100M1.3M7.8%
05
CRM
SALESFORCE INC
$87M330K6.8%
06
CRNX
CRINETICS PHARMACEUTICALS IN
$76M1.6M5.9%
07
VRDN
VIRIDIAN THERAPEUTICS INC
$74M2.4M5.8%
08
MPLT
MAPLIGHT THERAPEUTICS INC
$65M3.7M5.0%
09
ZBIO
ZENAS BIOPHARMA INC
$53M1.4M4.1%
10
N69605108
PHARVARIS N V
$49M1.8M3.8%

Filing history

2025Q4Dec 31
$1.3B 26.4%
24 positionsView →
2025Q3Sep 30
$1.0B 28.1%
20 positionsView →
2025Q2Jun 30
$1.4B 58.7%
29 positionsLocked
2025Q1Mar 31
$893M 45.9%
25 positionsLocked
2024Q4Dec 31
$1.7B 18.0%
34 positionsLocked
2024Q3Sep 30
$2.0B 8.5%
37 positionsLocked
2024Q2Jun 30
$1.9B 28.0%
38 positionsLocked
2024Q1Mar 31
$1.4B 10.5%
35 positionsLocked
2023Q4Dec 31
$1.6B 19.7%
36 positionsLocked
2023Q3Sep 30
$1.4B 4.6%
40 positionsLocked
2023Q2Jun 30
$1.3B 14.6%
41 positionsLocked
2023Q1Mar 31
$1.5B 5.4%
47 positionsLocked
Showing 12 of 64